Literature DB >> 14664793

Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain.

Haiyan Fu1, Joseph Muenzer, Richard J Samulski, George Breese, Jerillyn Sifford, Xinhua Zeng, Douglas M McCarty.   

Abstract

The blood-brain barrier is the main obstacle to efficient delivery of therapeutic reagents, including viral vectors, into the central nervous system (CNS) for treating global CNS diseases. In this study, the effects of mannitol infusions on global brain gene expression of a novel AAV vector were examined after intravenous (i.v.) or intracisternal injection. Initially, a self-complementary adeno-associated virus serotype 2 vector (scAAV) was compared to traditional single-stranded AAV2 vector for reporter gene expression in the brain of adult mice with or without pretreatment of an i.v. mannitol infusion. One to two months postinjection, analysis of vector-transduced green fluorescent protein (GFP) expression in the brain revealed that vector delivery to the CNS via i.v. injection required pretreatment with mannitol. This expression was observed only when scAAV vectors were used. Using these conditions, transgene expression was observed in various neurons and glial cells throughout the brain. The peripherally administered scAAV vectors also transduced the cells in multiple somatic tissues with efficient expression in liver (20-30% of hepatocytes), but was less efficient in other somatic tissues. Intracisternal injection of scAAV vector produced a broad and intense transgene expression in both neurons and glial cells in the CNS of injected mice ranging from the olfactory area to the brain stem and spinal cord. More than 50% of the Purkinje cells in the cerebellum expressed GFP. Intravenous infusion of mannitol before intracisternal injection of the scAAV vector enhanced the dispersion of the vector in the CNS. Further optimization of these steps combining peripheral and intracisternal scAAV gene delivery should facilitate the development of treatments for global CNS diseases, especially diseases involving both the somatic system and the CNS, such as lysosomal storage disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664793     DOI: 10.1016/j.ymthe.2003.08.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  68 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Dissecting local circuits in vivo: integrated optogenetic and electrophysiology approaches for exploring inhibitory regulation of cortical activity.

Authors:  Jessica A Cardin
Journal:  J Physiol Paris       Date:  2011-09-19

3.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

4.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

Review 5.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

6.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

7.  Visualization of spinal afferent innervation in the mouse colon by AAV8-mediated GFP expression.

Authors:  D J Schuster; J A Dykstra; M S Riedl; K F Kitto; C N Honda; R S McIvor; C A Fairbanks; L Vulchanova
Journal:  Neurogastroenterol Motil       Date:  2012-12-18       Impact factor: 3.598

8.  Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier.

Authors:  Bruno M D C Godinho; Nils Henninger; James Bouley; Julia F Alterman; Reka A Haraszti; James W Gilbert; Ellen Sapp; Andrew H Coles; Annabelle Biscans; Mehran Nikan; Dimas Echeverria; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Mol Ther       Date:  2018-08-08       Impact factor: 11.454

9.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

10.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.